Stock REDX REDX PHARMA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Redx Pharma Plc London S.E.

Equities

REDX

GB00BSNB6S51

Market Closed - London S.E.
Other stock markets
 11:46:01 2024-04-30 am EDT 		5-day change 1st Jan Change
15 GBX +31.58% Intraday chart for Redx Pharma Plc +66.67% -31.82%

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • With an enterprise value anticipated at 4.81 times the sales for the current fiscal year, the company turns out to be overvalued.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
REDX PHARMA PLC Stock Redx Pharma Plc
-31.82% 69.98M -
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
B+
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
B+
ARGENX SE Stock argenx SE
+4.40% 22.94B
B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
B+
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.16B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. 0RX Stock
  4. REDX Stock
  5. Ratings Redx Pharma Plc